BlackRock discloses 1.76% stake in Mural Oncology

LONDON - Investment management corporation BlackRock (NYSE:BLK), Inc. has disclosed a 1.76% stake in Mural Oncology plc, as per a recent filing with the Irish Takeover Panel. The disclosure, made public on April 16, 2025, follows the rules set by the 1997 Irish Takeover Panel Act and the Takeover Rules of 2022, which mandate the reporting of interests in relevant securities representing 1% or more.

The position, held by BlackRock as of April 15, 2025, includes 305,249 ordinary shares in the biotechnology firm, which specializes in cancer treatments. The filing also reported a return of stock on loan involving 2,600 shares but did not indicate any cash-settled or stock-settled derivatives or short positions associated with Mural Oncology securities.

This disclosure is a routine regulatory requirement and does not necessarily indicate an active change in BlackRock’s investment strategy or a pending transaction. No further details about the nature of the dealings or future acquisition or disposal plans were provided in the disclosure, and no supplemental Form 8 was attached.

The news of BlackRock’s stake in Mural Oncology is expected to be of interest to investors and market watchers, as BlackRock is one of the world’s leading investment managers. However, the disclosure does not imply any endorsement or assessment of Mural Oncology’s value or prospects.

The information for this report is based on a press release statement, which is a common source of factual data for financial news. The disclosure to the Regulatory Information Service, as required by the rules, was managed by Jana Blumenstein, with contact available through the London Stock Exchange (LON:LSEG).

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.